Cardiometabolic interventions - focus on transcriptional regulators.

Area of Science:

• Cardiovascular medicine
• Diabetology
• Clinical immunology

Background:

• Cardiovascular disease (CVD) is a major health burden, exacerbated by rising type II diabetes mellitus rates.
• The metabolic syndrome concept highlights the convergence of risk factors for CVD and diabetes.
• Intervention at this intersection offers a unified strategy to target both conditions.

Purpose of the Study:

• To discuss the basic science and clinical development of cardiometabolic interventions.
• To explore strategies for future drug development targeting metabolic syndrome.

Main Methods:

• Review of existing literature on PPAR-α and PPAR-γ agonists.
• Analysis of clinical data for drugs targeting glucose, lipid, and lipoprotein metabolism.
• Examination of effects on vascular inflammation and atherosclerosis.

Main Results:

• PPAR-α and PPAR-γ agonists show potential for targeting metabolic dysfunction and vascular inflammation.
• Existing drugs like fibrates and thiazolidinediones (TZD) offer insights into therapeutic pathways.
• Research is accelerating into selective and dual PPAR agonists for cardiometabolic intervention.

Conclusions:

• Targeting the metabolic syndrome intersection is a promising strategy for simultaneous CVD and diabetes risk reduction.
• Further research into PPAR agonists and future drug development is crucial for optimal cardiometabolic intervention.